Centessa shares surge after Lilly unveils $6.3 billion takeover deal

Eli Lilly will acquire Centessa Pharmaceuticals for $38 per share in cash (~$6.3B upfront) plus a non-transferable contingent value right up to $9/share, valuing the deal at up to $7.8B and representing a 40.5% premium to Centessa’s 30‑day VWAP. Centessa surged over 46% premarket; the acquisition gives Lilly ownership of an orexin receptor‑2 agonist pipeline including cleminorexton (targeting narcolepsy types 1 & 2 and idiopathic hypersomnia). The deal is expected to close in Q3 and is framed as a strategic expansion of Lilly’s neuroscience capabilities.

Analysis

Lilly’s move materially re-prioritizes large-cap pharma optionality toward orexin biology and neuro-centric M&A. Beyond the headline, the highest-probability second-order effect is a re-rating of near-term sleep/neuroscience assets: acquirers will now pay not only for clinical progress but for ownership of mechanism expertise and fast-to-clinic talent pools, which tightens valuations for similarly staged targets by a multiple twiddle (expect 20–40% bid-premium compression on remaining private assets).

Operationally, watch demand pressure on specialized CROs and manufacturing capacity for CNS-biologics and small-molecule neuro agents—a stepped-up acquisition cadence will increase lead-time for trials and CMC work, raising trial costs by an estimated 10–20% for the cohort vying to scale. Payer dynamics are the overlooked lever: payers will push for narrow labels and step edits on costly ‘best-in-class’ claims, compressing peak sales multiples if label expansion stalls.

Near-term reversal risks are binary clinical/regulatory outcomes and integration execution: the CVR-like optionality embedded in the transaction concentrates upside on future milestones while leaving acquirer downside on pricing and opportunity cost. For investors, that argues for option-structured exposure to capture asymmetric upside and for short/hedge plays that isolate the deal spread and broader small-cap neuroscience froth.

Key Decisions for Investors

• Buy LLY via 9–18 month call spread (size 1–2% NAV). Rationale: capped-cost way to capture accelerated neuroscience optionality without paying full delta; target 2.5–3x payoff vs premium if pipeline milestones or multiple expansion occur. Max loss = premium paid; take profits on >50% move in implied move or after next pivotal readout.
• Risk-arbitrage CNTA (size up to 0.5% NAV) only if residual spread to implied deal consideration >1.5%; hedge biotech beta by shorting XBI (~0.8x notional). Expected return 3–6% over months if deal closes; tail risk -25–40% on deal termination or regulatory scare—keep stop-loss at -10% absolute or unwind hedge ratio if volatility spikes.
• Trim SMCI and APP momentum exposure and redeploy into the LLY call-spread trade (reallocate ~1–2% NAV). Rationale: reduce momentum cyclicality and lock gains; redeploy into higher-conviction, event-driven healthcare upside with clearer binary catalysts over 12–24 months.
• Monitor and short small-cap orexin/sleep targets that reprice >30–40% above pre-deal comps (screen threshold: EV >$400M with no Phase 3). Rationale: M&A re-rating likely overshoots; expected downside -30% on failure to produce robust Phase 2/3 data within 12–24 months; keep position sizes small and pair with XBI long to hedge sector beta.